Jefferies Predicts Biogen Earnings Beat and Share Price Movement
1 report, 1 independent
Updated Oct 6
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Jefferies predicts that Biogen will slightly beat third-quarter earnings per share, expected at $2.14 against a consensus of $2.07, when the company reports on October 28. The firm also expects a share price move of 5% to 15% based on the company's upcoming clinical data.
Why it matters
The prediction is based on Biogen potentially reiterating or raising its 2026 revenue guidance, which currently implies 3% to 7% growth. Furthermore, the company is scheduled to report two Phase III datasets for litifilimab, an antibody for systemic lupus erythematosus, in the fourth quarter.
Who's involved
- BiogenAmerican multinational biotechnology company expected to report earnings and clinical trial results
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.